Affinity Biosensors

Affinity Biosensors is a private, commercial-stage diagnostics company focused on addressing the critical need for rapid antimicrobial susceptibility testing (AST). Its core innovation, the LifeScale platform, uses patented population profiling technology—measuring the mass of individual bacteria—coupled with artificial intelligence to generate accurate phenotypic AST results in approximately 4.5 hours, significantly faster than traditional methods. With FDA clearances for its system and a clear application in bloodstream infections caused by dangerous Gram-negative pathogens, the company is positioned in the high-growth AST market driven by antimicrobial resistance. Its business model centers on selling instruments and consumable test kits to clinical laboratories.

LifeScale platform using microfluidic single-cell mass sensing (Population Profiling) and AI analytics for rapid phenotypic antimicrobial susceptibility testing.

Competes directly with established phenotypic AST systems like bioMérieux's Vitek and Phoenix, BD's Bruker systems, and Accelerate Diagnostics' Accelerate Pheno. Also faces competition from genotypic/molecular methods that detect resistance genes faster but may not capture all phenotypic resistance. Affinity's differentiation is the speed of a phenotypic result using its unique mass-sensing technology.